Table 4.
Univariate and multivariate analysis of the preoperative risk factors related to tumour recurrence
| Risk factors |
Univariate analysis |
Multivariate analysis |
|||
| 3-yr RFS rate (%) | HR (95%CI) | Log-rank P value | Exp(b) (95%CI) | P value | |
| Pre-TACE radiological and laboratory evaluation | |||||
| Exceeding Milan criteria | 77.7 vs 91.2 | 3.41 (0.78-14.92) | 0.074 | ||
| Exceeding UCSF criteria | 60.6 vs 92.8 | 5.06 (0.78-32.74) | 0.011 | 4.69 (1.14-19.30) | 0.033 |
| Multiple nodules | 77.2 vs 93.4 | 4.33 (1.06-17.72) | 0.049 | 1.77 (0.27-11.48) | 0.550 |
| AFP > 400 ng/mL | 80.0 vs 85.3 | 1.96 (0.13-30.81) | 0.520 | ||
| NLR > 4 | 100 vs 80.4 | NA | 0.185 | ||
| PLR > 150 | 50.0 vs 88.6 | 5.98 (0.06-573.48) | 0.059 | ||
| Pre-LT radiological and laboratory evaluation | |||||
| mRECIST non response | 71.2 vs 94.3 | 6.96 (1.54-31.50) | 0.006 | 9.19 (1.65-51.30) | 0.012 |
| EASL non response | 76.8 vs 91.6 | 3.67 (0.82-16.34) | 0.056 | ||
| AFP > 400 ng/mL | 83.3 vs 89.0 | 4.74 (0.29-77.77) | 0.034 | 1.43 (0.23-9.10) | 0.703 |
| AFP increase > 15 ng/mL per month | 41.7 vs 87.7 | 3.89 (0.30-50.72) | 0.072 | ||
| NLR > 4 | 80.8 vs 87.9 | 1.54 (0.25-9.41) | 0.594 | ||
| NLR increase > 0.24/mo | 83.3 vs 100 | NA | 0.114 | ||
| PLR > 150 | 50.0 vs 89.1 | 5.32 (0.28-101.01) | 0.022 | 5.95 (1.04-33.95) | 0.046 |
| PLR increase > 3.04 | 80.8 vs 88.7 | 1.48 (0.24-9.04) | 0.636 | ||
RFS: Recurrence-free survival; HR: Hazard ratio; TACE: Transarterial chemoembolization; USCF: University of California San Francisco; AFP: Alpha-fetoprotein; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; LT: Liver transplantation; mRECIST: Modified Response Evaluation Criteria in Solid Tumours; EASL: European Association for the Study of the Liver.